OBJECTIVES: Individual data sources contain non-integrated data components needed to assess outcomes, resource use, and costs in cancer patients. This work describes methodology to integrate disparate electronic data sources in chronic myelogenous leukemia (CML) patients with a common identifier (CI). METHODS: A CML Patient cohort from the Huntsman Cancer Institute was created by extracting information across the Utah Cancer Registry; the Utah Population Database (UPDB); and the Enterprise Data Warehouse, including Cerner inpatient and EPIC ambulatory care clinic data. Medication use was from inpatient medication orders. A unique patient index identifier linked disparate records. RESULTS: A total of 602 patients were identified by ICD-9 diagnosis code for CML (250.1, 205.10-12) from 1995 through 2009, median age ϭ 51, 42.6% female. Of these 598 (99.3%) were linked to the UPDB and 245 had a state death certificate. Charlson Comorbidity Index (CCI) analysis (ϩ/Ϫ 90 days) identified 232 (38.5%) subjects with a score of zero, 199 (33.1%) with 1-3, 99 (16.4%) with 4-6, 47 (7.8%) with 7-9 and 25 (4.2%) with a score of 10-17 (medianϭ2, meanϭ 2.6, and SDϭ 3.1). Inpatient admission data was available for 380 (63.1%) patients, with a total of 267 CML related drug orders. Procedures were observed for 531 (88.2%) patients. Lab results were available for 564 (93.7%) subjects. Of those, BCR/ABL biomarker results were available for 210 (37.2% of all lab results) patients. CONCLUSIONS: Integrating data across different data sources in an academic health care center with a National Comprehensive Cancer Network hospital can provide comprehensive health care data. This methodology may influence the evolution of electronic health records, as a data resource tool for outcomes data, resource use and cost utilization across complex disease states such as CML. Future research will expand on drug data sourcing and evaluate the medical record notes to evaluate CML specific outcomes.
OBJECTIVES:
In cancer research using claims data, identifying metastases is often essential yet difficult. The objective of this study was to examine the validity of algorithms identifying metastatic breast (BC), lung (LC), or colorectal (CRC) cancer in healthcare claims data. METHODS: A proprietary clinical cancer database containing physician-reported clinical data on patients with BC, LC, or CRC between January 1, 2007 and March 31, 2010 , was linked to claims data. Inclusion required health plan enrollment Ͼ 3 months prior to the initial clinical cancer diagnosis date. Un-validated claims algorithms from previous research were identified. A generic metastatic algorithm with all metastatic ICD-9 codes and tumor-specific variations of the algorithm were assessed for validity. The algorithms' validity versus the clinically reported metastases was tested using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: Of 14,480 patients in the database, 4631 BC (mean age 53.6 yr), 2449 LC (mean age 62.9 yr), and 2058 CRC patients (mean age 58.3 yr) met inclusion criteria. Metastases at diagnosis were recorded in 8.0% (371) of BC, 49.2% (1204) of LC, and 25.7% (528) of CRC patients. The tumor specific algorithm for identifying metastatic BC had 53.2% sensitivity and 98.6% specificity; PPV and NPV were 77.6 and 95.8. The lung-specific algorithm had 55.2% sensitivity and 85.3% specificity; PPV and NPV were 81.0 and 62.6. Similarly, the CRC-specific algorithm had 59.4% sensitivity, 89.8% specificity, with PPV 72.9 and NPV 82.7. The generic algorithm had lower specificity and higher sensitivity for all 3 cancers and a significantly lower PPV for breast cancer. CONCLUSIONS: Specificity, but not sensitivity, was high for all tumor-specific algorithms. Although not tested, better sensitivity might be gained by including chemotherapy in the algorithms for some tumor types.
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AVAILABILITY OF LABORATORY RESULTS DATA IN A CLAIMS DATABASE IN THE UNITED STATES
Horne LN, Ming EE, Doyle c AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA OBJECTIVES: To describe the frequency of available laboratory results data in a commercial healthcare database, among patients who are being treated for diabetes or dyslipidemia and who have have at least one documented laboratory result for a hemoglobin a1c (HbA1c) or lipid test. METHODS: The source population was adults continuously enrolled in a large U.S. health plan during 2009 with at least one CPT code for a HbA1c or lipid test. Laboratory results data were considered available if LOINC codes or free text identified a result recorded within ϩ/Ϫ 3 days of the CPT claim date. The final study cohort included only patients with at least one result available. We calculated the 1-year person-level percent of the number of tests ordered in 2009 that had results available. Results for each test were stratified by whether the patient received an antidiabetic or antidyslipidemia drug during the same year. RESULTS: Overall, a result was available for 41% of HbA1c tests and 42% of lipid tests. Persons with at least one prescription claim for an antidiabetic or antidyslipidemia drug had more frequent tests recorded during the study period (HbA1c: mean 4.5 with drug, 2.0 without drug; Lipid: mean 3.9 with drug, 2.0 without drug). However, results were less likely to be consistently available among treated patients: 44% of those treated (among whom 70% of tests had results), and 39% of those not treated (among whom 83% of tests had results) had any results available. CONCLUSIONS: While laboratory data may enhance studies conducted in administrative claims databases, results may be inconsistently available. In this study, among treated patients, 44% had any laboratory results recorded, for whom results were missing approximately 30% of the time. An evaluation of the completeness of laboratory data prior to any study is feasible and may help understand any potential bias. 
OBJECTIVES:
To demonstrate replication of the quantification of relationships between surrogates and endpoints as well as reconciliation with previous epidemiological studies; original studies for heart rate as a surrogatefor all-cause mortality, pain management and gastrointestinal adverse events, and treatment for diabetes and HbA1c and HbA1c and complications. METHODS: For heart rate, three epidemiological studies from three countries using a Weibull survival analysis and Generalized Estimating Equations were used; namely, the Coronary Artery Surgery Study (CASS), the Copenhagen City Heart Study (CCHS) and the General Practitioner Research Network (GPRN). These equations reproduced a meta-regression and meta-analysis of all available placebo-controlled clinical trials with heart rate as a prognostic factor for all-cause mortality. For pain, data consisted of 2005 Health Care Utilization Project (HCUP) and Premier. Logistic regressions were used to obtain evaluate and compare odds-ratios. In diabetes, Generalized Estimating Equations (GEE) allowing serially correlated behavior with repeated HbA1c reading at variable frequencies and durations between their measurement. RESULTS: Heart is consistently prognostic for all-cause mortality. Moreover, its quantification is consistent, 0.00694 (PϽ0.001) in CASS and 0.00683 (PϽ0.001) in CCHS (1981 CCHS ( -1983 and 0.00717 in CCHS (1991 CCHS ( -1993 with the Weibull. With the GEE, the coefficient is 0.0268 (Pϭ0.006) in GPRN, 0.0249 (Pϭ0.008) in the meta-regression of controlled clinical trials, and 0.01595 in the GEE with CCHS data. All three equations reproduced the published clinical trials with odd-ratios within 1/100ths.Conditional odds-ratios were replicated in measure between the two datasets for fecal impaction, postoperative illeus, other bowel obstruction, vomiting and abdominal pain. The diabetic equations were replicated exactly in 3 countries, treatment and HbA1c and complications with coefficients within 1/100 th in patients with newly diagnosed T2DM. CONCLUSIONS: These are three studies where the quantification of the relationship between a surrogate and and endpoint have beed replicated with precision and subsequently applied to clinical trials. 
PODIUM SESSION II: DRUG USE AND PATIENT SAFETY
DU1 COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
OBJECTIVES:
This study compared the risk of developing substance use disorder in children with Attention-Deficit/Hyperactivity Disorder (ADHD) utilizing stimulant and atomoxetine. METHODS: This study involved retrospective, propensity score matched cohort assessing the risk of developing substance use disorder among stimulant and atomoxetine users with ADHD using the IMS LifeLink Health Plan Claims Database. Adolescents between 12 and 18 years of age starting on stimulant or atomoxetine therapy from July 1, 2004 to December 31, 2005 were included in the study sample. Substance use disorder was classified into (i) tobacco use (ICD-9-CM code-305.1); (ii) drug abuse (ICD-9-CM codes-305. 2-305.9, 304.x, 292.x, 304.00-304.03, 304.70-304.73) ; and (iii) alcohol abuse 303.x, 305.0, 357.5, 425.5, 291.9, 571.0, 571.2, 571.3, 535.3, and 790.3) . Patients with stimulant and atomoxetine were matched on propensity scores calculated on the basis of baseline characteristics. Conditional logistic model was developed using the STRATA option to account for the matched pair design to assess the risk of substance use disorder development. Persistency measured as duration of therapy was included as a covariate in the final model along with other covariates which were significant after matching. RESULTS: The propensity score matched cohort consisted of 2,030 adolescents with ADHD in both the stimulant and atomoxetine user groups (total of 4,060 adolescents). Conditional logistic regression analysis did not show any statistically significant difference between stimulant or atomoxetine use and the risk of substance use development (Odds Ratio [OR]-0.86; 95% CI-0.29-2.50). Age was the only covariate that was significantly associated with the substance use disorder (OR-3.55; 95% CI-1.25-10.13). CONCLUSIONS: Utilization of stimulant was not significantly associated with higher risk of substance use disorder compared to atomoxetine in adolescents. More research is needed to evaluate the long-term effects of use of medications in ADHD.
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